Jabil
About: Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.
Employees: 138,000
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
134% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 53
44% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]
17% more capital invested
Capital invested by funds: $12.6B [Q3] → $14.8B (+$2.14B) [Q4]
7% more funds holding
Funds holding: 688 [Q3] → 733 (+45) [Q4]
0.97% less ownership
Funds ownership: 92.77% [Q3] → 91.8% (-0.97%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 247 | Existing positions reduced: 269
11% less call options, than puts
Call options by funds: $434M | Put options by funds: $488M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Barclays George Wang 83% 1-year accuracy 15 / 18 met price target | 10%upside $179 | Overweight Maintained | 20 Dec 2024 |
Stifel Matthew Sheerin 72% 1-year accuracy 21 / 29 met price target | 2%downside $160 | Buy Reiterated | 19 Dec 2024 |
UBS David Vogt 42% 1-year accuracy 5 / 12 met price target | 7%downside $152 | Neutral Maintained | 19 Dec 2024 |
Goldman Sachs Mark Delaney 63% 1-year accuracy 17 / 27 met price target | 2%downside $160 | Buy Maintained | 19 Dec 2024 |
Financial journalist opinion
Based on 11 articles about JBL published over the past 30 days









